Amylyx Pharmaceuticals, Inc. (AMLX)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

28.14 on 9 Oct 2026

2 buys23 sales at will3 planned sales

Fiscal year 2025, ended 31 Dec 2025, as filed

Revenue

$0.00

Net income

$144.74M

Free cash flow

$123.48M

Return on equity

-47.4%

Return on capital

-39.7%

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
5 Oct 2026	MILNE GEORGE M JR Director	Sold on a plan	$830.90K	3.7%
10 Sep 2026	Cohen Joshua B Co-Chief Executive Officer	Sold at will	$980.50K	0.8%
10 Sep 2026	Klee Justin B. Co-Chief Executive Officer	Sold at will	$980.26K	0.8%
10 Sep 2026	FRATES JAMES M Chief Financial Officer	Sold at will	$349.82K	4.4%
10 Sep 2026	Bedrosian Camille L Chief Medical Officer	Sold at will	$324.87K	3.5%
10 Sep 2026	Mazzariello Gina Chief Legal Officer	Sold at will	$309.51K	4.8%

40out of 100

Profitability 40

Financial strength 67

Growth 0

Insiders 58

Strongest on financial strength (67), weakest on growth (0). A score of the business, not of the price.

Last 12 months

Only here

Bought

$152.18K

2 buys, 1 buyer

Sold

$10.14M

26 sales

Planned sales

12%

under a 10b5-1 plan